Potential for Progress in the Therapeutics of Alzheimer’s Disease; Unanswered Questions
Publisher
Birkhäuser Boston
Reference13 articles.
1. Buxbaum JD, Oishi M, Chen HI, Pinkas-Kramarski R, Jaffe EA, Gandy SE and Greengard P (1992): Cholinergic agonists and interleukin-1 regulate processing and secretion of the Alzheimer’s β/A4 amyloid protein precursor. Proc Natl Acad Sci USA 89:10075–10078.
2. Davis KL, Hollister LE and Tepper J (1978): Cholinergic inhibition of methylphenidate induced steriotypy: Oxotremorine. Psychopharmacology 56:1–4.
3. Davis KL, Thai U, Gamzu ER et al. (1992): A double-blind, placebo controlled multicenter study of Tacrine for Alzheimer’s disease. N Eng. J Med. 327:1253–1259.
4. Eikelenboom Farber S, Nitsch R, Schulz J and Wurtman R (1995): Regulated secretion of β amyloid precursor protein in rat brain. The Journal of Neuroscience 15:7442–7451.
5. Farlow M, Gracon SI, Hershey LA, Lewis KW, Sadowsky CH, Dolan-Ureno I (1992): A controlled trial of Tacrine in Alzheimer’s disease. The Tacrine Study Group. JAMA 268(1 8):2523–2529.